Serum glial fibrillary acidic protein

Overview

Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein expressed predominantly by astrocytes in the central nervous system (CNS). It serves as a structural component of the astrocytic cytoskeleton and plays a fundamental role in maintaining cellular integrity, supporting myelination, and mediating responses to CNS injury. When astrocytes are damaged, stressed, or undergo reactive gliosis, GFAP is released into the extracellular space and subsequently enters the bloodstream, making serum and plasma GFAP (sGFAP) a measurable surrogate of astrocytic injury and neurodegeneration. Its elevation in peripheral blood reflects diverse CNS pathologies, ranging from acute traumatic brain injury to chronic neurodegenerative and neuroinflammatory diseases.

As a fluid biomarker, sGFAP has attracted substantial interest due to advances in ultrasensitive immunoassay platforms that enable reliable quantification at sub-picogram-per-milliliter concentrations in blood. Unlike invasive cerebrospinal fluid sampling, blood-based GFAP measurement offers a practical, scalable approach for disease monitoring, prognostication, and therapeutic response assessment. Its utility spans multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (mTBI), epilepsy, HIV-associated neurocognitive disorders, and aging-related cognitive decline, positioning sGFAP as one of the most broadly applicable CNS biomarkers in contemporary translational neuroscience.

Recent Publications Summary

Recent studies have continued to position serum glial fibrillary acidic protein (sGFAP) as a circulating marker of astroglial injury and disease progression across neurologic disorders. In multiple sclerosis, sGFAP is being evaluated as a retrospective marker of progression in the NeuroFilMS observational cohort, alongside prospective monitoring of serum neurofilament light chain (sNfL) for clinical and radiological activity 42419882Jul. A separate MS study reported that serum GFAP, together with retinal neuronal loss measured by optical coherence tomography, may provide additive prognostic information for disability progression 42127333May. Another MS cohort found that serum biomarkers, including GFAP, remained stable after switching from intravenous to subcutaneous natalizumab (Tysabri®), suggesting no obvious biomarker signal of subclinical disease activity after the route change 42332277Jun. A further assay-comparison study also examined serum GFAP for progression independent of relapse activity (PIRA) in MS and compared Elecsys and Simoa immunoassays using a large healthy-control reference database 41453834Dec.

Outside MS, sGFAP has been investigated as a marker of acute brain injury and neurodegeneration. In acute ischemic stroke, serum GFAP was elevated at all sampled time points after symptom onset compared with controls, with a temporal pattern showing an early rise and subsequent changes over the first week 42295622Jun. In mild traumatic brain injury, GFAP has been studied in combination with UCH-L1 for ruling out CT-detectable intracranial lesions, including in protocolized real-world emergency department implementation studies and retrospective implementation experience 42315262Jun42340459Jun. A nanophotonic biosensor platform also incorporated GFAP with S100B and UCH-L1 for multiplex stroke differentiation across serum, urine, and saliva, reporting strong analytical performance and clinical discrimination between ischemic stroke, intracerebral hemorrhage, and controls 42166366May. In postoperative pituitary adenoma patients, GFAP was among the circulating brain injury biomarkers assessed for associations with long-term fatigue and cognitive outcomes after transsphenoidal surgery 42384349Jul.

GFAP has also been explored in broader neurologic and systemic contexts. In Alzheimer’s disease research, capillary blood sampling studies found that GFAP measured from self-administered fingerprick samples correlated with venous biomarkers and with cognition and function in older adults, and appeared to be associated with vascular risk 42091863May. In a cohort of community-dwelling older adults, higher GFAP was associated with increased cognitive impairment risk and was linked in mediation analyses with homocysteine, hemoglobin, and other Alzheimer’s biomarkers including p-Tau181 and p-Tau217 41980534Apr. In amyotrophic lateral sclerosis, plasma GFAP was examined alongside NfL and pTau181 as part of distinct biological axes, with GFAP reported to be strongly associated with disease-related features in the abstracted results 42049146Apr. GFAP was also measured in people with HIV in the PRESTIGIO registry, where no evidence was found for higher biomarker levels in heavily treatment-experienced individuals; age, comorbidities, and CD4+ count were stronger predictors than resistance status 42207142May. Additional studies have assessed GFAP in temporal lobe epilepsy with comorbid depression 42189430May and in the context of biomarker implementation for mild traumatic brain injury 41825621Mar.

What Changes, What Holds

1. sGFAP is becoming a progression-oriented marker in multiple sclerosis, but its role remains adjunctive rather than settled
REINFORCES These studies strengthen the baseline view of serum GFAP as a blood marker of astrocytic injury and chronic CNS disease activity, while narrowing its MS use toward disability progression and multimodal risk stratification rather than relapse detection alone 42419882Jul42127333May. The natalizumab switch data also support biomarker stability when clinical status is unchanged 42332277Jun. What remains unsettled is whether GFAP adds enough independent prognostic value to become routine in MS care.

2. Serum GFAP is extending into acute injury triage and postoperative outcome research without displacing its established biomarker role
NEW DIRECTION Acute ischemic stroke and mild traumatic brain injury studies broaden the baseline account by placing sGFAP in emergency decision-making, especially for early injury detection and CT-negative triage 42295622Jun42315262Jun. That use is new relative to the overview’s emphasis on monitoring astrocytic injury and neurodegeneration, but it does not contradict it. The postoperative pituitary adenoma work further suggests possible links to longer-term recovery, though that application remains exploratory 42384349Jul.

3. Capillary sampling and multimarker analyses are making GFAP easier to measure and harder to interpret in isolation
METHOD Fingerprick sampling and nanophotonic multiplex platforms change how GFAP is obtained and combined with other analytes, rather than redefining what GFAP biologically represents 42091863May42166366May. These approaches support the baseline claim that ultrasensitive blood assays can make GFAP practical, but they mainly advance accessibility, multiplexing, and real-world deployment. The broader implication is that GFAP may be most useful as part of composite panels, where its signal can be interpreted alongside vascular, neuronal, or inflammatory markers.